前列腺癌盆腔淋巴结IMRT与仅前列腺IMRT的毒性比较:基于全国人群的研究
该研究利用英格兰国家医疗服务体系2010至2013年数据,比较高危或局部晚期前列腺癌患者接受前列腺及盆腔淋巴结IMRT(PPLN-IMRT)与仅前列腺IMRT(PO-IMRT)的毒性。结果显示两组3年重度胃肠和泌尿生殖毒性累积发生率相似,调整后无显著差异。结论认为包含盆腔淋巴结的放疗未增加3年毒性。
要点
- PPLN-IMRT与PO-IMRT的3年重度胃肠毒性累积发生率均为14%。
- 两组重度泌尿生殖毒性发生率分别为9%和8%,调整后无显著差异。
- 高危或局部晚期前列腺癌放疗包含盆腔淋巴结未增加3年毒性。
核心结论
- 高危或局部晚期前列腺癌放疗包含盆腔淋巴结与仅前列腺放疗相比,3年重度胃肠和泌尿生殖毒性无显著增加。
研究设计与样本
- PPLN-IMRT组780例,PO-IMRT组3065例,采用竞争风险回归分析调整患者和肿瘤特征。
主要发现
- PPLN-IMRT组和PO-IMRT组3年重度胃肠毒性累积发生率均为14%。
- PPLN-IMRT组3年重度泌尿生殖毒性累积发生率为9%,PO-IMRT组为8%。
临床怎么用
- 对于高危或局部晚期前列腺癌患者,放疗包含盆腔淋巴结未显示增加3年重度胃肠或泌尿生殖毒性,可作为临床决策参考。
- 晚期泌尿生殖毒性影响仍需更长期随访,当前结果不足以回答该问题。
局限性
- 随访时间有限,仅报告3年毒性,晚期毒性需进一步随访。
- 毒性识别基于行政数据库中的操作和诊断编码,可能存在遗漏或误分类。
- 本研究为观察性设计,不能完全排除混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is a debate about the effectiveness and toxicity of pelvic lymph node (PLN) irradiation for the treatment of men with high-risk prostate cancer. This study compared the toxicity of intensity-modulated radiation therapy (IMRT) to the prostate and the pelvic lymph nodes (PPLN-IMRT) with prostate-only IMRT (PO-IMRT). MATERIALS AND METHODS: Patients with high-risk localized or locally advanced prostate cancer treated with IMRT in the English National Health Service between 2010 and 2013 were identified by using data from the Cancer Registry, the National Radiotherapy Dataset, and Hospital Episode Statistics, an administrative database of all hospital admissions. Follow-up was available up to December 31, 2015. Validated indicators were used to identify patients with severe toxicity according to the presence of both a procedure code and diagnostic code in patient Hospital Episode Statistics records. A competing risks regression analysis, with adjustment for patient and tumor characteristics, estimated subdistribution hazard ratios (sHRs) by comparing GI and genitourinary (GU) complications for PPLN-IMRT versus PO-IMRT. RESULTS: Three-year cumulative incidence in the PPLN-IMRT (n = 780) and PO-IMRT (n = 3,065) groups was 14% for both groups for GI toxicity, and 9% and 8% for GU toxicity, respectively. Patients receiving PPLN-IMRT and PO-IMRT had similar levels of severe GI (adjusted sHR, 1.00; 95% CI, 0.80 to 1.24; P = .97) and GU (adjusted sHR, 1.10; 95% CI, 0.83 to 1.46; P = .50) toxicity rates. CONCLUSION: Including PLNs in radiation fields for high-risk or locally advanced prostate cancer is not associated with increased GI or GU toxicity at 3 years. Additional follow-up is required to answer questions about its impact on late GU toxicity. Results from ongoing trials will provide insight into the anticancer effectiveness of PLN irradiation.
引用
- Parry MG, Sujenthiran A, Cowling TE, et al. Treatment-Related Toxicity Using Prostate-Only Versus Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy: A National Population-Based Study. J Clin Oncol. 2019. PMID: 31163009. doi:10.1200/JCO.18.02237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。